Loading patent…
AssigneeTexas Biotechnology Corporation
InventorsTimothy P. Kogan, Kaijun Ren, Peter Vanderslice, Pamela J. Beck
Estimating the term…
The present invention is directed to an isolated and purified cyclic peptide of from 5 to about 13 residues modeled after a portion of the CS1 peptide. A peptide of this invention preferably has the amino acid residue sequence of SEQ ID NO:2-14 or 16-42. The present invention is further directed to a process of selectively inhibiting the binding of α4β1 integrin to a protein such as VCAM-1, fibronectin or invasin. In accordance with that process, a cell that expresses α4β1 integrin is exposed to that protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition containing a physiologically acceptable carrier and a cyclic peptide of the invention.
A cyclic disulfide peptide of from 6 to about 8 amino acid residues that inhibits the binding of the integrin α4β1 to VCAM-1 or fibronectin, the peptide having (a) an N-terminal Cys-amine group;
A cyclic disulfide peptide of from 6 to about 8 amino acid residues that inhibits the binding of the integrin α4β1 to VCAM-1 or fibronectin, the peptide having (a) an N-terminal amine group;
Dependencies are inferred from the claim text.